MA61003A1 - Immunocytokine pour activer le récepteur il-10ra humain et son utilisation - Google Patents

Immunocytokine pour activer le récepteur il-10ra humain et son utilisation

Info

Publication number
MA61003A1
MA61003A1 MA61003A MA61003A MA61003A1 MA 61003 A1 MA61003 A1 MA 61003A1 MA 61003 A MA61003 A MA 61003A MA 61003 A MA61003 A MA 61003A MA 61003 A1 MA61003 A1 MA 61003A1
Authority
MA
Morocco
Prior art keywords
immunocytokine
receptor
activating
human
methods
Prior art date
Application number
MA61003A
Other languages
English (en)
Other versions
MA61003B1 (fr
Inventor
Stanislav Rudolfovich Evdokimov
Pavel Andreevich Iakovlev
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Iana Andreevna Smirnova
Sergei Andreevich Ageev
Vladimir Sergeevich Tsympilov
Aleksey Vladimirovich Kononov
Iuliia Viktorovna Evdokimovskaia
Elena Sergeevna Kolosova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020140807A external-priority patent/RU2810750C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA61003A1 publication Critical patent/MA61003A1/fr
Publication of MA61003B1 publication Critical patent/MA61003B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention relève du domaine de la biotechnologie et de la médecine, et concerne en particulier une immunocytokine pour activer le récepteur il-10ra humain. L'invention concerne en outre des acides nucléiques codant pour ladite immunocytokine, des vecteurs d'expression, des cellules hôtes et leurs procédés de production, des procédés de production de l'immunocytokine, des compositions pharmaceutiques comprenant ladite immunocytokine, des compositions pharmaceutiques comprenant l'immunocytokine ci-dessus et d'autres composés thérapeutiquement actifs, des méthodes de traitement d'une maladie oncologique et des utilisations de l'immunocytokine ou leurs compositions pharmaceutiques pour le traitement d'une maladie oncologique.
MA61003A 2020-12-10 2021-12-10 Immunocytokine pour activer le récepteur il-10ra humain et son utilisation MA61003B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020140807A RU2810750C2 (ru) 2020-12-10 Иммуноцитокин для активации IL-10Rα рецептора человека и его применение
PCT/RU2021/050432 WO2022124950A1 (fr) 2020-12-10 2021-12-10 Immunocytokine pour activer le récepteur il-10ra humain et son utilisation

Publications (2)

Publication Number Publication Date
MA61003A1 true MA61003A1 (fr) 2023-10-31
MA61003B1 MA61003B1 (fr) 2024-12-31

Family

ID=81973601

Family Applications (1)

Application Number Title Priority Date Filing Date
MA61003A MA61003B1 (fr) 2020-12-10 2021-12-10 Immunocytokine pour activer le récepteur il-10ra humain et son utilisation

Country Status (21)

Country Link
US (1) US20240034764A1 (fr)
EP (1) EP4259644A4 (fr)
JP (1) JP2023553934A (fr)
KR (1) KR20230118919A (fr)
CN (1) CN117120461A (fr)
AR (1) AR124310A1 (fr)
AU (1) AU2021398529A1 (fr)
CA (1) CA3201656A1 (fr)
CL (1) CL2023001677A1 (fr)
CO (1) CO2023007563A2 (fr)
CR (1) CR20230243A (fr)
EC (1) ECSP23043458A (fr)
IL (1) IL303501A (fr)
JO (1) JOP20230129A1 (fr)
MA (1) MA61003B1 (fr)
MX (1) MX2023006830A (fr)
PE (1) PE20241070A1 (fr)
PY (1) PY21108779A (fr)
TW (1) TW202237631A (fr)
UY (1) UY39562A (fr)
WO (1) WO2022124950A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150645A1 (es) * 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2015117930A1 (fr) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Immunoconjugués d'interleukine 10
US20200353050A1 (en) * 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
EP3927728A2 (fr) * 2019-02-21 2021-12-29 Xencor, Inc. Protéines de fusion fc d'il-10 non ciblées et ciblées

Also Published As

Publication number Publication date
MA61003B1 (fr) 2024-12-31
CA3201656A1 (fr) 2022-06-16
AU2021398529A9 (en) 2024-10-24
JOP20230129A1 (ar) 2023-06-08
EP4259644A1 (fr) 2023-10-18
MX2023006830A (es) 2023-07-06
JP2023553934A (ja) 2023-12-26
CN117120461A (zh) 2023-11-24
WO2022124950A1 (fr) 2022-06-16
US20240034764A1 (en) 2024-02-01
ECSP23043458A (es) 2023-07-31
TW202237631A (zh) 2022-10-01
KR20230118919A (ko) 2023-08-14
PE20241070A1 (es) 2024-05-13
AU2021398529A1 (en) 2023-06-29
CL2023001677A1 (es) 2024-01-19
CR20230243A (es) 2023-07-13
PY21108779A (es) 2022-08-11
IL303501A (en) 2023-08-01
EP4259644A4 (fr) 2024-10-16
AR124310A1 (es) 2023-03-15
UY39562A (es) 2022-05-31
CO2023007563A2 (es) 2023-07-21

Similar Documents

Publication Publication Date Title
Maekawa et al. Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway
Kim et al. Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm
Tursi et al. Bacterial amyloid curli acts as a carrier for DNA to elicit an autoimmune response via TLR2 and TLR9
Zhang et al. TLR2-dependent modulation of osteoclastogenesis by Porphyromonas gingivalis through differential induction of NFATc1 and NF-κB
Zhang et al. Biofilm inhibition and elimination regulated by cationic conjugated polymers
Takami et al. Stimulation by toll-like receptors inhibits osteoclast differentiation
Wright et al. Characterization of a bacterial tyrosine kinase in Porphyromonas gingivalis involved in polymicrobial synergy
Deng et al. Prostacyclin-producing human mesenchymal cells target H19 lncRNA to augment endogenous progenitor function in hindlimb ischaemia
WO2022216787A3 (fr) Nanoparticules lipidiques et leurs méthodes d'utilisation
Chen et al. Characteristics and influencing factors of amyloid fibers in S. mutans biofilm
MA39225A1 (fr) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
Blancas-Luciano et al. Macrophages immunomodulation induced by Porphyromonas gingivalis and oral antimicrobial peptides
Han et al. Effect of human periodontal ligament stem cell-derived extracellular vesicles on macrophage pyroptosis and periodontal inflammatory injury in periodontitis
Balducci et al. The human amniotic fluid stem cell secretome triggers intracellular Ca2+ oscillations, NF‐κB nuclear translocation and tube formation in human endothelial colony‐forming cells
Huang et al. Autophagy-mediated circHIPK2 promotes lipopolysaccharide-induced astrocytic inflammation via SIGMAR1
MA35411B1 (fr) Nouvelle composition thérapeutique contenant de l'apomorphine comme principe actif
MA61003A1 (fr) Immunocytokine pour activer le récepteur il-10ra humain et son utilisation
Rafiee et al. Maprotiline inhibits COX2 and iNOS gene expression in lipopolysaccharide-stimulated U937 macrophages and carrageenan-induced paw edema in rats
Mourad et al. Antisenescence therapy improves function in a human model of cardiac fibrosis-on-a-chip
WO2022192594A3 (fr) Molécules d'acide nucléique et vaccins les comprenant pour la prévention et le traitement d'infections à coronavirus et de maladie
Lin et al. Sulfated glycosaminoglycans are host epithelial cell targets of the Candida albicans toxin candidalysin
Zhang et al. Dissolvable microneedle patch enables local delivery of immunomodulatory microparticles containing bifunctional molecules for periodontal tissue regeneration
Zhou et al. Confined mechanical microenvironment regulated antibiotic resistance in 3D biofilm aggregates probed by scanning electrochemical microscopy
Yan et al. Mechanotransduction in Shaping Immunity: Pathways, Crosstalk, and Pathophysiological Relevance
Li et al. RGS10 negatively regulates apical periodontitis via TFEB‐mediated autophagy in BABL/c mice model and in vitro